Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
18 Years and older, Male and Female
Summary
The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001
versus investigator's choice of chemotherapy in patients with advanced nasopharyngeal
carcinoma (NPC).
By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, PDR001 leads to the
activation of a T-cell mediated antitumor immune response.
Objectives
This was an open-label, multi-center, randomized, and controlled Phase II study to evaluate
the efficacy and safety of spartalizumab versus investigator's choice of treatment in
subjects with moderately differentiated/undifferentiated locally advanced recurrent or
metastatic NPC who progressed on or after first-line treatment.
Participants who met the inclusion/exclusion criteria were randomized in a 2:1 ratio to
either investigational arm (spartalizumab) or control arm (commonly used chemotherapy as per
investigator's choice). Participants treated with spartalizumab could continue treatment
until confirmed progressive disease as per immune-related response criteria (irRC).
Participants in the chemotherapy arm were allowed to crossover to spartalizumab if they had
radiological progression as per Response Evaluation Criteria In Solid Tumors version 1.1
(RECIST v1.1) documented by an independent central review and the Investigator believed this
was the best treatment option for the patient.
Eligibility
- Histologically documented non-keratinizing locally advanced recurrent or metastatic NPC.
- Must be resistant to platinum-based chemotherapy (defined as progression on or after platinum-based chemotherapy given in the recurrent/metastatic setting).
- May have received at least 1 prior therapy for recurrent or metastatic disease, up to 2 prior systemic therapies.
- An archival tumor specimen or newly obtained tumor sample may be submitted at screening/baseline (a fresh tumor sample is preferred), unless agreed differently between Novartis and the Investigator.
- At least 1 measurable lesion (as per RECIST v1.1) progressing or new since last anti-tumor therapy.
- Prior treated brain or meningeal metastases must be without MRI evidence of progression for at least 8 weeks and off systemic steroids for at least 2 weeks prior to screening/baseline.
- Patient must be willing to undergo testing for human immunodeficiency virus (HIV) if not tested within the past 6 months. If HIV+ positive, patient will be eligible if: his/ her CD4+ count = 300/µL; his/her viral load is undetectable; he/she is currently receiving highly active antiretroviral therapy (HAART).
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.